Expertise in
6
conditions

Jean-philippe P. Metges

Brest, FR 
Expertise in
6
conditions
Brest, FR 

Overview

Jean-philippe Metges practices practicing medicine in Brest, France.

Mr. Metges is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Dihydropyrimidine Dehydrogenase Deficiency, Esophageal Cancer, Colorectal Cancer, and Stomach Cancer.

He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 11 clinical trials.

Gender

Male

Locations

Brest, France
Other Locations
Besancon, France
Paul, France
Rennes, France
Angers, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Study Phase: Phase 3
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Drug
Study Drugs: Association atezolizumab, BDB001
Study Phase: Phase 2
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2025
Intervention Type: Drug
Study Phase: Phase 3
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 4
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drugs: EndoTAG-1, Gemcitabine
Study Phase: Phase 3
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drugs: Eryaspase, Gemcitabine, Abraxane, Irinotecan, 5-FU, Leucovorin
Study Phase: Phase 3
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer
A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer
Enrollment Status: Completed
Publish Date: May 17, 2021
Intervention Type: Drug
Study Drug: Tinzaparin
Study Phase: Phase 3
View 9 Less Clinical Trials

53 Total Publications

Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma.
Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma.
Journal: Frontiers in medicine
Published: January 15, 2026

Frequently Asked Questions about Jean-philippe P. Metges

Is Jean-philippe P. Metges a top-rated expert for Dihydropyrimidine Dehydrogenase Deficiency?

MediFind is an objective health platform that identifies experts based on real-world data. Jean-philippe P. Metges is classified as an Distinguished expert for Dihydropyrimidine Dehydrogenase Deficiency, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean-philippe P. Metges participate in research or clinical trials?

Yes. Jean-philippe P. Metges has published 53 articles and abstracts on conditions like Dihydropyrimidine Dehydrogenase Deficiency. You can view a list of Jean-philippe P. Metges's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Metges's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile